• Futures are rising while oil prices are dropping due to hopes for a U.S.-Iran deal.
• Major companies like Apple, Amazon, and Meta are set to report earnings soon. • A potential Federal Reserve rate hike is being discussed. • Investors are shifting focus from AI stocks to energy and healthcare sectors. • Eli Lilly's stock is performing well, hitting an all-time high before a slight pullback. • Market turmoil continues as investors adopt defensive strategies.
Direxion Daily LLY Bull 2X Shares
ELIL----
Share your thoughts
Write something you'd like to share with our community...
- F
If there is something for us to cheer about in the market, its $XLE and some names like $Eli Lilly(LLY.US) $Johnson & Johnson(JNJ.US) $Abbvie(ABBV.US). Lily especially is giving us something to hope for. I will hold longer.
- H
📢 𝗝𝗨𝗦𝗧 𝗜𝗡: Eli Lilly Delays Retatrutide Approval Filing to Q1 2027 - $Eli Lilly(LLY.US) $Hims & Hers Health(HIMS.US) $Novo Nordisk AS(NVO.US)
👉 𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀:➤ 𝗘𝗹𝗶 𝗟𝗶𝗹𝗹𝘆 plans to file for 𝗿𝗲𝘁𝗮𝘁𝗿𝘂𝘁𝗶𝗱𝗲 approval in 𝗤𝟭 𝟮𝟬𝟮𝟳.➤ Filing delayed to gather additional 𝗺𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 and quality-control data.➤ Phase 3 trials met primary endpoints in two additional studies.➤ Adults with obesity and Type 2 diabetes lost up to 𝗮𝗻 𝗮𝘃𝗲𝗿𝗮𝗴𝗲 𝗼𝗳 𝟮𝟬.𝟴% body weight.➤ Adults with severe obesity and cardiovascular disease lost up to 𝗮𝗻 𝗮𝘃𝗲𝗿𝗮𝗴𝗲 𝗼𝗳 𝟮𝟮.𝟲% body weight.➤ Retatrutide targets 𝗚𝗟𝗣-𝟭, 𝗚𝗜𝗣, and 𝗴𝗹𝘂𝗰𝗮𝗴𝗼𝗻 hormones.➤ Common side effects included 𝗱𝗶𝗮𝗿𝗿𝗵𝗲𝗮, 𝗻𝗮𝘂𝘀𝗲𝗮, and 𝗰𝗼𝗻𝘀𝘁𝗶𝗽𝗮𝘁𝗶𝗼𝗻.➤ TD Cowen estimates retatrutide could generate $𝟯.𝟴 𝗯𝗶𝗹𝗹𝗶𝗼𝗻 in 𝟮𝟬𝟯𝟬 sales.➤ Novo Nordisk recently sued Lilly over 𝗮𝗹𝗹𝗲𝗴𝗲𝗱 false advertising claims.👉 𝗘𝘅𝗽𝗲𝗿𝘁 𝗦𝘁𝗮𝘁𝗲𝗺𝗲𝗻𝘁:𝗞𝗲𝗻𝗻𝗲𝘁𝗵 𝗖𝘂𝘀𝘁𝗲𝗿, President of Lilly Cardiometabolic Health:"We believe we have the information necessary to file for approval globally for retatrutide as a potential treatment for obesity, knee osteoarthritis pain and obstructive sleep apnea." - H
📢 𝗝𝗨𝗦𝗧 𝗜𝗡: $Eli Lilly(LLY.US) Eli Lilly's Retatrutide Delivers Up to 22.6% Weight Loss in Phase 3 Trials
👉 𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀:➤ 𝗘𝗹𝗶 𝗟𝗶𝗹𝗹𝘆 reports positive 𝗣𝗵𝗮𝘀𝗲 𝟯 results for retatrutide.➤ 𝗧𝗥𝗜𝗨𝗠𝗣𝗛-𝟮 achieved average 𝟮𝟬.𝟴% (𝟰𝟵.𝟲 𝗹𝗯𝘀) weight loss at 𝟭𝟮 mg.➤ Placebo group lost 𝟰.𝟬% (𝟵.𝟯 𝗹𝗯𝘀) in 𝗧𝗥𝗜𝗨𝗠𝗣𝗛-𝟮.➤ 𝗔𝟭𝗖 declined by up to 𝟭.𝟲% from a 𝟳.𝟳% baseline.➤ 𝗧𝗥𝗜𝗨𝗠𝗣𝗛-𝟯 achieved average 𝟮𝟮.𝟲% (𝟱𝟱.𝟴 𝗹𝗯𝘀) weight loss at 𝟭𝟮 mg.➤ Retatrutide reduced triglycerides by 𝟯𝟳.𝟬%, non-HDL cholesterol by 𝟭𝟲.𝟱%.➤ Systolic blood pressure declined by an average of 𝟵.𝟯 mmHg.➤ 𝗠𝗔𝗖𝗘 analyses did not reach statistical significance as confidence intervals crossed 𝟭.𝟬.➤ Lilly plans to submit an 𝗙𝗗𝗔 Biologics License Application in 𝗤𝟭 𝟮𝟬𝟮𝟳. - H
📢 𝐉𝐔𝐒𝐓 𝐈𝐍: Novo Nordisk Sues Eli Lilly in U.S. Federal Court, Alleging Claim Under the Lanham Act, Court Records Show - $Novo Nordisk AS(NVO.US) $Eli Lilly(LLY.US)
- F
• Dow futures fell while oil prices rose due to escalating attacks in Iran.
• Three U.S. servicemembers were killed in the attacks. • Key earnings reports from Google, Tesla, Intel, and GE Vernova are upcoming. • Gilead faces challenges with HIV treatments as patent expirations approach. • Eli Lilly is highlighted for strong earnings performance and is in a buy zone. • Intel prepares for its Q2 earnings report amid a chip market sell-off. • Biotech stocks remain attractive to investors despite AI stock declines. - H
📢 𝐉𝐔𝐒𝐓 𝐈𝐍: EU Approves Novo Nordisk's Oral Wegovy for Obesity Treatment - $Novo Nordisk AS(NVO.US) $Hims & Hers Health(HIMS.US) $Eli Lilly(LLY.US)
👉 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:➤ 𝐄𝐮𝐫𝐨𝐩𝐞𝐚𝐧 𝐂𝐨𝐦𝐦𝐢𝐬𝐬𝐢𝐨𝐧 approves 𝐨𝐫𝐚𝐥 𝐖𝐞𝐠𝐨𝐯𝐲 𝟐𝟓 𝐦𝐠.➤ Approval covers adults with 𝐨𝐛𝐞𝐬𝐢𝐭𝐲 or overweight with comorbidities.➤ Oral Wegovy becomes Novo Nordisk's 𝐟𝐢𝐟𝐭𝐡 regulatory approval globally.➤ OASIS 4 trial showed approximately 𝐒𝟕% mean weight loss over 64 weeks.➤ Placebo group recorded approximately 𝐒𝟑% mean weight loss.➤ Around 𝐨𝐧𝐞 𝐢𝐧 𝐭𝐡𝐫𝐞𝐞 participants lost 𝐒𝟐𝟎% or more body weight.➤ EU also approved 𝐖𝐞𝐠𝐨𝐯𝐲 𝟕.𝟐 𝐦𝐠 single-dose injection pen.➤ Novo Nordisk says the injection delivers approximately 𝐒𝟐𝟏% weight loss.➤ Company plans additional global launches in 𝐭𝐡𝐞 𝐬𝐞𝐜𝐨𝐧𝐝 𝐡𝐚𝐥𝐟 𝐨𝐟 𝟐𝟎𝟐𝟔.👉 𝐄𝐱𝐩𝐞𝐫𝐭 𝐒𝐭𝐚𝐭𝐞𝐦𝐞𝐧𝐭:𝐌𝐢𝐤𝐞 𝐃𝐨𝐮𝐬𝐭𝐝𝐚𝐫, president and CEO of Novo Nordisk:"For many people, a tablet may be a simpler and more acceptable way to start and continue treatment." - H
$Eli Lilly(LLY.US) | Bernstein SocGen Group maintains 𝐎𝐮𝐭𝐩𝐞𝐫𝐟𝐨𝐫𝐦 on 𝐄𝐥𝐢 𝐋𝐢𝐥𝐥𝐲, 𝐫𝐚𝐢𝐬𝐞𝐬 𝐏𝐓 𝐭𝐨 $𝟏𝟑𝟖𝟓
Analyst sees a path to a slight Q2 beat and raise, despite a weaker Foundayo launch and the stock's significant premium valuation.
- M
As an Eli Lilly shareholder, I am encouraged by the company's leadership in diabetes and weight-loss treatments, which continue to drive strong revenue growth. Its promising drug pipeline also supports long-term potential.
For me, the key questions are whether Eli Lilly can sustain strong earnings growth, maintain its leadership in obesity and diabetes treatments, and continue developing successful new medicines to drive future growth.
Trade Showcase: Trade, Show & Earn Rewards! - H
$Eli Lilly(LLY.US) | 𝐂𝐚𝐧𝐭𝐨𝐫 𝐅𝐢𝐭𝐳𝐠𝐞𝐫𝐚𝐥𝐝 maintains 𝐎𝐯𝐞𝐫𝐰𝐞𝐢𝐠𝐡𝐭 on 𝐄𝐥𝐢 𝐋𝐢𝐥𝐥𝐲, 𝐫𝐚𝐢𝐬𝐞𝐬 𝐏𝐓 𝐭𝐨 $𝟏𝟑𝟓𝟎
Analyst sees strong 2Q26 biopharma results and guidance raises providing a fundamentals-driven tailwind to support outperformers like LLY.
- H
📢 𝐉𝐔𝐒𝐓 𝐈𝐍: Absci prices $100M stock offering with Eli Lilly among investors - $Absci(ABSI.US) $Eli Lilly(LLY.US)
- H
📢 𝐉𝐔𝐒𝐓 𝐈𝐍: Eli Lilly Plans Europe Launch of Weight-Loss Pill in Late 2026 or Early 2027 - $Eli Lilly(LLY.US) $Novo Nordisk AS(NVO.US) $Hims & Hers Health(HIMS.US)
👉 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:➤ 𝐄𝐥𝐢 𝐋𝐢𝐥𝐥𝐲 plans to launch its weight-loss pill in Europe and Britain in 𝐇𝟐 𝟐𝟎𝟐𝟔 or early 𝟐𝟎𝟐𝟕.➤ Launch timing depends on obtaining 𝐫𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 approvals across target markets.➤ Lilly will initially target the 𝐨𝐮𝐭-𝐨𝐟-𝐩𝐨𝐜𝐤𝐞𝐭 telehealth market.➤ Strategy mirrors Lilly's 𝐔.𝐒. direct-to-consumer obesity business model.➤ The company plans partnerships with 𝐭𝐞𝐥𝐞𝐡𝐞𝐚𝐥𝐭𝐡 providers and digital health platforms.➤ Lilly says obesity treatment outside the U.S. is largely 𝐩𝐚𝐭𝐢𝐞𝐧𝐭-𝐩𝐚𝐢𝐝.➤ The drug recently secured approvals in the 𝐔.𝐒. and 𝐔𝐀𝐄.➤ Lilly will continue pursuing 𝐠𝐨𝐯𝐞𝐫𝐧𝐦𝐞𝐧𝐭 reimbursement where available.➤ U.S. 𝐦𝐨𝐬𝐭-𝐟𝐚𝐯𝐨𝐮𝐫𝐞𝐝-𝐧𝐚𝐭𝐢𝐨𝐧 pricing policies may affect negotiations.👉 𝐖𝐡𝐲 𝐈𝐭 𝐌𝐚𝐭𝐭𝐞𝐫𝐬:➤ Expands Lilly's presence in the rapidly growing 𝐠𝐥𝐨𝐛𝐚𝐥 obesity treatment market.➤ Telehealth-focused distribution could accelerate 𝐩𝐚𝐭𝐢𝐞𝐧𝐭 access and adoption.➤ European expansion may create a significant new 𝐫𝐞𝐯𝐞𝐧𝐮𝐞 opportunity for Lilly.👉 𝐄𝐱𝐩𝐞𝐫𝐭 𝐒𝐭𝐚𝐭𝐞𝐦𝐞𝐧𝐭:➤ "Our goal will still be public coverage, wherever possible." — 𝐏𝐚𝐭𝐫𝐢𝐤 𝐉𝐨𝐧𝐬𝐬𝐨𝐧, Executive Vice President of Lilly's International Businesses.➤ "MFN will play a role for all launches." — 𝐏𝐚𝐭𝐫𝐢𝐤 𝐉𝐨𝐧𝐬𝐬𝐨𝐧. - H
$Eli Lilly(LLY.US) | Cantor Fitzgerald reiterates 𝐎𝐯𝐞𝐫𝐰𝐞𝐢𝐠𝐡𝐭 on 𝐄𝐥𝐢 𝐋𝐢𝐥𝐥𝐲, maintains 𝐏𝐓 𝐚𝐭 $𝟏,𝟐𝟑𝟎
Analyst notes a weekly dip in injectable obesity prescriptions (-3%) but a rise in orals (+2%), with Foundayo's launch trajectory tracking similarly to Wegovy.
- M
Eli Lilly continues to benefit from strong demand for its diabetes and weight-loss treatments, which have become major growth drivers. The company also has a promising pipeline that could support future earnings growth. However, the stock trades at a premium valuation, meaning investors are expecting continued success in both its current products and future drug development efforts.
Trade Showcase: Trade, Show & Earn Rewards! - H
📢 𝐉𝐔𝐒𝐓 𝐈𝐍: Novo Nordisk to Seek China Approval for Oral Wegovy Within Months - $Novo Nordisk AS(NVO.US) $Eli Lilly(LLY.US) $Hims & Hers Health(HIMS.US)
👉 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:➤ Novo Nordisk plans to file for China approval of oral Wegovy within months.➤ CEO Mike Doustdar announced the timeline during his first China visit as CEO.➤ Oral weight-loss drugs target patients reluctant to use injections.➤ Novo and Eli Lilly are competing for China's obesity treatment market.➤ Lilly submitted a China marketing application for orforglipron in late 2025.➤ China's semaglutide patent expired in March; data protection lasts until early 2027.➤ Novo expects generic competition beginning in Q2 2027.➤ Novo says large-scale manufacturing could be a key barrier for competitors.➤ Oral Wegovy has secured approvals in the U.S. and U.K., with a U.S. launch underway.➤ China GLP-1 sales reached about Yuan 1.4 billion ($207 million) in Q1. - H
$Eli Lilly(LLY.US) | BMO Capital 𝐫𝐞𝐢𝐭𝐞𝐫𝐚𝐭𝐞𝐬 𝐎𝐮𝐭𝐩𝐞𝐫𝐟𝐨𝐫𝐦 on 𝐄𝐥𝐢 𝐋𝐢𝐥𝐥𝐲, maintains 𝐏𝐓 𝐚𝐭 $𝟏𝟑𝟎𝟎
Analyst sees early data for acquired JAK2i AJ1-11095 as highly competitive and potentially best-in-class, supporting Lilly's business development strategy.
- F
$Eli Lilly(LLY.US) is ready to give a face ripper with this weekly setup. A monster breakout pending.
- H
📢 𝐉𝐔𝐒𝐓 𝐈𝐍: Novo Nordisk's Wegovy Pill Approved in UK for Weight Management - $Novo Nordisk AS(NVO.US) $Hims & Hers Health(HIMS.US) $Eli Lilly(LLY.US)
👉 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:➤ UK approves 𝐖𝐞𝐠𝐨𝐯𝐲 𝐩𝐢𝐥𝐥, oral semaglutide for weight management.➤ UK becomes 𝐄𝐮𝐫𝐨𝐩𝐞'𝐬 𝐟𝐢𝐫𝐬𝐭 country authorizing the treatment.➤ Approved for adults with 𝐨𝐛𝐞𝐬𝐢𝐭𝐲 or weight-related conditions.➤ Medication to be used alongside 𝐝𝐢𝐞𝐭 and 𝐞𝐱𝐞𝐫𝐜𝐢𝐬𝐞.➤ Novo expects availability via 𝐩𝐫𝐢𝐯𝐚𝐭𝐞 𝐩𝐫𝐞𝐬𝐜𝐫𝐢𝐩𝐭𝐢𝐨𝐧 within weeks.➤ OASIS 4 trial: 𝐚𝐩𝐩𝐫𝐨𝐱𝐢𝐦𝐚𝐭𝐞𝐥𝐲 𝟏𝟒% weight loss versus 2% placebo.➤ Treatment-adherent participants achieved 𝐚𝐩𝐩𝐫𝐨𝐱𝐢𝐦𝐚𝐭𝐞𝐥𝐲 𝟏𝟕% weight loss.➤ Most common side effects were 𝐠𝐚𝐬𝐭𝐫𝐨𝐢𝐧𝐭𝐞𝐬𝐭𝐢𝐧𝐚𝐥 symptoms.➤ About 𝟕% discontinued treatment due to adverse events.➤ Approval follows authorizations from 𝐅𝐃𝐀 and 𝐔𝐀𝐄 regulators. - H
📊 𝐈𝐍𝐕𝐄𝐒𝐓𝐎𝐑 𝐍𝐎𝐓𝐄 Goldman Sachs lifts global obesity-drug forecast to $114bn by 2030 as oral GLP-1s go mainstream - $Hims & Hers Health(HIMS.US) $Novo Nordisk AS(NVO.US) $Eli Lilly(LLY.US)
Goldman Sachs raised its forecast for the global obesity-drug market to $114bn by 2030, up roughly 13% from a $101bn projection in December, citing rapid adoption of oral GLP-1 obesity drugs and a shift from a niche, high-price segment to a mass-consumer market. - N
The STI remains rather resilient, recovering most of what it lost on Friday. Although the Singapore Market is often labelled as "boring" and "slow investment", volatile periods show the true strength of our own local stock market. Still in for the long term.
☕️ [Task Coins Giveaway] Daily Market Talk — Tesla Robotaxi Goes Live
Tesla's Austin robotaxi launches without safety drivers, Intel jumps 11% on Google order, Marvell selected for S&P 500, US blacklists Alibaba and Tencent.
